MCID: CPL005
MIFTS: 27

Capillary Disease

Categories: Cardiovascular diseases

Aliases & Classifications for Capillary Disease

MalaCards integrated aliases for Capillary Disease:

Name: Capillary Disease 12 15
Disease of Capillaries 12 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1271
ICD10 33 I78 I78.9
ICD9CM 35 448
SNOMED-CT 68 57223003 58729003
UMLS 73 C0155765

Summaries for Capillary Disease

Disease Ontology : 12 A vascular disease that is located in the capillaries.

MalaCards based summary : Capillary Disease, also known as disease of capillaries, is related to pure red-cell aplasia and hypersplenism, and has symptoms including petechiae of skin An important gene associated with Capillary Disease is IL2 (Interleukin 2), and among its related pathways/superpathways are Photodynamic therapy-induced NF-kB survival signaling and Cytokines and Inflammatory Response. The drugs Dexamethasone and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include skin and the capillaries, and related phenotype is endocrine/exocrine gland.

Related Diseases for Capillary Disease

Diseases related to Capillary Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Related Disease Score Top Affiliating Genes
1 pure red-cell aplasia 10.2 ALB IL2
2 hypersplenism 10.1 ALB CSF2
3 smallpox 10.1 CSF2 IL2
4 hydrops, lactic acidosis, and sideroblastic anemia 10.1 ALB SERPING1
5 testicular disease 10.1 ALB IL2
6 leprosy 3 10.1 ALB IL2
7 drug allergy 10.1 ALB ATP12A
8 pulmonary sarcoidosis 10.1 CSF2 IL2
9 filariasis 10.1 ALB IL2
10 hereditary hemorrhagic telangiectasia 10.1
11 mastitis 10.1 ALB CSF2
12 primary bacterial infectious disease 10.1 ALB IL2
13 mucositis 10.1 CSF2 IL2
14 immune deficiency disease 10.1 IL2 SERPING1
15 capillary leak syndrome 10.1 ALB CSF2 IL2
16 acquired immunodeficiency syndrome 10.1 ALB CSF2 IL2
17 respiratory system disease 10.1 ALB CSF2 IL2
18 fungal esophagitis 10.0 ATP12A ATP4A
19 diclofenac allergy 10.0 ATP12A ATP4A
20 gastroduodenal crohn's disease 10.0 ATP12A ATP4A
21 neonatal candidiasis 10.0 ATP12A ATP4A
22 photoallergic dermatitis 10.0 ATP12A ATP4A
23 squamous papillomatosis 10.0 ATP12A ATP4A
24 toxic megacolon 10.0 ATP12A ATP4A
25 aspiration pneumonitis 10.0 ATP12A ATP4A
26 gastrointestinal neuroendocrine benign tumor 10.0 ATP12A ATP4A
27 granulomatous gastritis 10.0 ATP12A ATP4A
28 esophageal candidiasis 10.0 ATP12A ATP4A
29 gastric neuroendocrine neoplasm 10.0 ATP12A ATP4A
30 acute laryngitis 10.0 ATP12A ATP4A
31 laryngitis 10.0 ATP12A ATP4A
32 duodenitis 10.0 ATP12A ATP4A
33 rumination disorder 10.0 ATP12A ATP4A
34 active peptic ulcer disease 10.0 ATP12A ATP4A
35 congenital disorder of deglycosylation 10.0 ATP12A ATP4A
36 bladder calculus 10.0 ATP12A ATP4A
37 ischemic neuropathy 10.0 ATP12A ATP4A
38 bile reflux 10.0 ATP12A ATP4A
39 peptic esophagitis 10.0 ATP12A ATP4A
40 leukocyte disease 10.0 CSF2 IL2
41 dyskinesia of esophagus 10.0 ATP12A ATP4A
42 myeloma, multiple 10.0 ALB CSF2 IL2
43 hernia, hiatus 10.0 ATP12A ATP4A
44 anismus 10.0 ATP12A ATP4A
45 postsurgical hypothyroidism 10.0 ATP12A ATP4A
46 lymphocytic colitis 10.0 ATP12A ATP4A
47 esophageal atresia/tracheoesophageal fistula 10.0 ATP12A ATP4A
48 clostridium difficile colitis 10.0 ATP12A ATP4A
49 diarrhea 1, secretory chloride, congenital 10.0 ATP12A ATP4A
50 laryngeal tuberculosis 10.0 ATP12A ATP4A

Graphical network of the top 20 diseases related to Capillary Disease:



Diseases related to Capillary Disease

Symptoms & Phenotypes for Capillary Disease

UMLS symptoms related to Capillary Disease:


petechiae of skin

MGI Mouse Phenotypes related to Capillary Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.1 ALB ARHGAP5 ATP4A CSF2 CTC1 IL2

Drugs & Therapeutics for Capillary Disease

Drugs for Capillary Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 275)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 1177-87-3
3
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 53-03-2 5865
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
6
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 302-25-0
7
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
8
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Not Applicable 2921-57-5
9
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3 26787-78-0 33613
10
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
11
Clarithromycin Approved Phase 4,Phase 2,Phase 3 81103-11-9 84029
12
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
13
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
14
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
15
Bosentan Approved, Investigational Phase 4,Phase 2 147536-97-8 104865
16
Vincristine Approved, Investigational Phase 4,Phase 2,Phase 3 57-22-7, 2068-78-2 5978
17
Azathioprine Approved Phase 4,Phase 3,Not Applicable 446-86-6 2265
18
Hydroxychloroquine Approved Phase 4 118-42-3 3652
19
Cilazapril Approved Phase 4 92077-78-6, 88768-40-5 56330 56329
20
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
21
Enalaprilat Approved Phase 4 76420-72-9 6917719
22
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
23
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
24
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
25
Eprosartan Approved Phase 4 133040-01-4 5281037
26
Trandolapril Approved Phase 4 87679-37-6 5484727
27
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
28
Spirapril Approved Phase 4 83647-97-6 5311447
29
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
30
Bisoprolol Approved Phase 4 66722-44-9 2405
31
Fosinopril Approved Phase 4 98048-97-6 55891
32
Captopril Approved Phase 4 62571-86-2 44093
33
Nebivolol Approved, Investigational Phase 4 99200-09-6, 152520-56-4, 118457-14-0 71301
34
Losartan Approved Phase 4 114798-26-4 3961
35
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
36
Ramipril Approved Phase 4 87333-19-5 5362129
37
Caffeic acid Experimental, Investigational Phase 4,Phase 3 331-39-5 1549111
38
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Phase 3,Not Applicable 2920-86-7
39
Candesartan Experimental Phase 4 139481-59-7 2541
40 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Not Applicable
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
44 glucocorticoids Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
45 Antioxidants Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
46 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
47 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
48 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 365)
# Name Status NCT ID Phase Drugs
1 Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
2 Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research(VOYAGER)Study Completed NCT00460213 Phase 4 Valsartan 80mg daily;Valsartan 160mg daily
3 PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs Completed NCT02249897 Phase 4 CHOLESTYRAMINE
4 The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis Completed NCT02480335 Phase 4 bosentan
5 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
6 The Study of Different Dose Rituximab in the Treatment of ITP Completed NCT03258866 Phase 4 Rituximab;Rituximab
7 A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT01390649 Phase 4
8 High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
9 A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4 Eltrombopag olamine
10 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
11 Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
12 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
13 NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients Recruiting NCT02817360 Phase 4 RAS-antagonist and beta-blocker up-to maximal dosages
14 Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Recruiting NCT03771378 Phase 4 rhTPO;eltrombopag
15 Atorvastatin in Management of Newly Diagnosed ITP Recruiting NCT03692754 Phase 4 Atorvastatin 20mg;Atorvastatin 10mg
16 The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
17 Immunomodulation With Romiplostim in Young Adults With ITP Recruiting NCT02760251 Phase 4 romiplostim
18 Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment Active, not recruiting NCT02614898 Phase 4
19 Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS Active, not recruiting NCT02574403 Phase 4 eculizumab
20 Erythropoietin in Hemolytic Uremic Syndrome Not yet recruiting NCT03776851 Phase 4 erythropoietin
21 Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura Not yet recruiting NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
22 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP) Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
23 Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura Withdrawn NCT01754545 Phase 4 Octaplas infusion and placebo (group 1);Octaplas infusion and placebo (group 2)
24 DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP Patients Unknown status NCT02834468 Phase 3 DEX Combined With RTX, CSA and IVIG
25 Thrombocytopenia in Gestational Period Unknown status NCT02751593 Phase 2, Phase 3 Dexamethasone
26 Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients Unknown status NCT02877212 Phase 3 Eltrombopag
27 A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy Unknown status NCT02391272 Phase 3 rhTPO
28 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy Unknown status NCT02270801 Phase 3 rhTPO
29 Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
30 Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP Unknown status NCT01805648 Phase 3 rhTPO
31 Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Completed NCT01295736 Phase 3 Sildenafil;placebo
32 Effects of Saxagliptin on Endothelial Function Completed NCT01319357 Phase 3 Saxagliptin;Placebo
33 Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch Completed NCT00275509 Phase 3 Thymoglobulin;Daclizumab;Mycophenolate mofetil;Tacrolimus;Dexamethasone;Prednisone;Cytogam
34 Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Completed NCT00406393 Phase 3 Tacrolimus;Methotrexate;Sirolimus
35 Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP) Completed NCT02868099 Phase 3 Romiplostim;Placebo
36 Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone Completed NCT02914054 Phase 2, Phase 3 High dose Dexamethasone pulses;Prednisone
37 Caffeic Acid Tablets as a Second-line Therapy for ITP Completed NCT02351622 Phase 3 Caffeic acid;Dexamethasone;Placebo
38 Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura Completed NCT02553317 Phase 3
39 An Investigation of rhTPO With Different Frequencies in the Management of ITP Completed NCT02139501 Phase 3 Recombinant Human Thrombopoietin (rhTPO)
40 An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia Completed NCT02063789 Phase 3 Human immunoglobulin intravenous
41 Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia Completed NCT02334813 Phase 3 Prednisone;Dexamethasone
42 Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU Completed NCT02205541 Phase 3 Eculizumab;Placebo
43 A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT02201290 Phase 3 Eltrombopag Tablets;Eltrombopag PfOS
44 A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT02076412 Phase 3 Fostamatinib Disodium;Placebo
45 A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT02076399 Phase 3 Fostamatinib disodium;Placebo
46 Eltrombopag Phase III Study In Chinese Chronic ITP Patients Completed NCT01762761 Phase 3 eltrombopag;placebo
47 rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP Completed NCT01734044 Phase 3 recombinant human thrombopoietin (rhTPO); dexamethasone;Dexamethasone
48 Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients Completed NCT01730352 Phase 2, Phase 3 H. pylori triple therapy
49 Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) Completed NCT01438840 Phase 3 Avatrombopag;Placebo;Standard of care
50 Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia Completed NCT01349790 Phase 3 NewGam

Search NIH Clinical Center for Capillary Disease

Genetic Tests for Capillary Disease

Anatomical Context for Capillary Disease

MalaCards organs/tissues related to Capillary Disease:

41
Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Capillary Disease:

19
The Capillaries

Publications for Capillary Disease

Articles related to Capillary Disease:

# Title Authors Year
1
Growth hormone, sorbitol, and diabetic capillary disease. ( 4102056 )
1971
2
Growth hormone, sorbitol, and diabetic capillary disease. ( 4100908 )
1971

Variations for Capillary Disease

Expression for Capillary Disease

Search GEO for disease gene expression data for Capillary Disease.

Pathways for Capillary Disease

Pathways related to Capillary Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.76 CSF2 IL2
2 10.09 CSF2 IL2

GO Terms for Capillary Disease

Cellular components related to Capillary Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.02 ALB ATP4A CSF2 IL2 SERPING1

Biological processes related to Capillary Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 potassium ion import across plasma membrane GO:1990573 9.4 ATP12A ATP4A
2 potassium ion import GO:0010107 9.37 ATP12A ATP4A
3 ATP hydrolysis coupled proton transport GO:0015991 9.32 ATP12A ATP4A
4 cellular sodium ion homeostasis GO:0006883 9.26 ATP12A ATP4A
5 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.16 ATP12A ATP4A
6 cellular potassium ion homeostasis GO:0030007 8.96 ATP12A ATP4A
7 sodium ion export across plasma membrane GO:0036376 8.62 ATP12A ATP4A

Molecular functions related to Capillary Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP12A ATP4A
2 potassium:proton exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A

Sources for Capillary Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....